These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 18822711)

  • 1. [Bevacizumab in the treatment of colorectal carcinoma: news from ASCO 2008].
    Mansueto G; Longo F
    Tumori; 2008; 94(4):suppl 1-14. PubMed ID: 18822711
    [No Abstract]   [Full Text] [Related]  

  • 2. Perforating dermatosis in a patient receiving bevacizumab.
    Vano-Galvan S; Moreno C; Medina J; Pérez-García B; García-López JL; Jaén P
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):972-4. PubMed ID: 19470057
    [No Abstract]   [Full Text] [Related]  

  • 3. Pathologic complete response to neoadjuvant FOLFOX in combination with bevacizumab in unresectable metastatic colorectal carcinoma.
    Duffy A; Shia J; Huitzil-Melendez FD; Fong Y; O'Reilly EM
    Clin Colorectal Cancer; 2008 Mar; 7(2):140-3. PubMed ID: 18501074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use cetuximab after oxaliplatin-based chemotherapy in a patient with metastatic colorectal cancer.
    Malik Z; Eng C
    Clin Adv Hematol Oncol; 2007 Jan; 5(1 Suppl 1):4-7. PubMed ID: 17491584
    [No Abstract]   [Full Text] [Related]  

  • 5. [Advances in the treatment of metastatic colorectal cancer with bevacizumab].
    Longo F; Mansueto G
    Tumori; 2006; 92(5):suppl 1-12. PubMed ID: 17168449
    [No Abstract]   [Full Text] [Related]  

  • 6. First description of an uterine perforation potentially imputable to treatment with bevacizumab.
    Uguen T; Leconte B; Desgrippes R; Tchoundeu B; Bretagne JF; Manfredi S
    Acta Oncol; 2012 Nov; 51(8):1102-4. PubMed ID: 23020310
    [No Abstract]   [Full Text] [Related]  

  • 7. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.
    Schwartzberg LS; Rivera F; Karthaus M; Fasola G; Canon JL; Hecht JR; Yu H; Oliner KS; Go WY
    J Clin Oncol; 2014 Jul; 32(21):2240-7. PubMed ID: 24687833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver resection after FOLFOX with bevacizumab.
    Mickle M; Mulcahy MF
    Clin Adv Hematol Oncol; 2007 Jan; 5(1 Suppl 1):12-4. PubMed ID: 17491587
    [No Abstract]   [Full Text] [Related]  

  • 9. Current role of bevacizumab in colorectal cancer.
    Saltz L
    Clin Adv Hematol Oncol; 2009 Jun; 7(6):375-6. PubMed ID: 19606071
    [No Abstract]   [Full Text] [Related]  

  • 10. Dual biologic therapy in the first-line mCRC setting: implications of the CAIRO2 study.
    Chu E
    Clin Colorectal Cancer; 2008 Jul; 7(4):226. PubMed ID: 18650190
    [No Abstract]   [Full Text] [Related]  

  • 11. Aneurysm formation in an angiomyolipoma during bevacizumab combination therapy.
    Maleux G; Vaninbroukx J; Heye S; van Cutsem E; Oyen R
    Acta Oncol; 2010 Aug; 49(6):864-6. PubMed ID: 20230212
    [No Abstract]   [Full Text] [Related]  

  • 12. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
    Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
    Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Systemic therapy for colorectal cancer].
    Pestalozzi BC; Jäger D; Knuth A
    Chirurg; 2005 Jun; 76(6):570-2, 574. PubMed ID: 15905968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
    Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
    Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study.
    Sogabe S; Komatsu Y; Yuki S; Kusumi T; Hatanaka K; Nakamura M; Kato T; Miyagishima T; Hosokawa A; Iwanaga I; Sakata Y; Asaka M
    Jpn J Clin Oncol; 2011 Apr; 41(4):490-7. PubMed ID: 21303790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver resection following FOLFOXIRI plus bevacizumab: a detailed pathological review.
    Walter H; Thomas AL
    Br J Cancer; 2013 Jun; 108(12):2417-8. PubMed ID: 23801031
    [No Abstract]   [Full Text] [Related]  

  • 17. Bevacizumab plus irinotecan-based regimens in the treatment of metastatic colorectal cancer.
    Heinemann V; Hoff PM
    Oncology; 2010; 79(1-2):118-28. PubMed ID: 21088438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer.
    Dohn LH; Jensen BV; Larsen FO
    Acta Oncol; 2010 Apr; 49(3):395-6. PubMed ID: 20001495
    [No Abstract]   [Full Text] [Related]  

  • 19. Highlights from the 42nd Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, June 2006.
    Clin Colorectal Cancer; 2006 Jul; 6(2):109-13. PubMed ID: 16945165
    [No Abstract]   [Full Text] [Related]  

  • 20. Accrual delayed in adjuvant bevacizumab trial.
    Tuma RS
    J Natl Cancer Inst; 2006 Apr; 98(7):439-40. PubMed ID: 16595779
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.